PMID- 17694504
OWN - NLM
STAT- MEDLINE
DCOM- 20080321
LR  - 20171116
IS  - 1520-7552 (Print)
IS  - 1520-7552 (Linking)
VI  - 24
IP  - 2
DP  - 2008 Feb
TI  - Circulating advanced glycation end products (AGEs) and soluble form of receptor 
      for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant 
      protein-1 (MCP-1) levels in patients with type 2 diabetes.
PG  - 109-14
AB  - BACKGROUND: Atherosclerosis is an inflammatory disease. Monocyte chemoattractant 
      protein-1 (MCP-1) is an essential chemokine responsible for the recruitment of 
      monocytes to inflammatory lesions in the vasculature, an initial step of 
      atherosclerosis. Since serum levels of MCP-1 are higher in patients with type 2 
      diabetes, inhibition of MCP-1 may be a novel therapeutic target for prevention of 
      accelerated atherosclerosis in diabetes. However, little is known about the 
      regulation and determinants of serum MCP-1 levels in patients with diabetes. In 
      this study, we examined the determinants of serum MCP-1 levels in type 2 diabetic 
      patients. METHODS: Eighty-six consecutive outpatients with type 2 diabetes (36 
      male and 50 female; mean age 68.4+/-9.6) underwent a complete history and 
      physical examination, determination of blood chemistries, MCP-1, tumour necrosis 
      factor-alpha, adiponectin, advanced glycation end products (AGEs), and soluble 
      form of receptor for AGEs (sRAGE). We examined the association between MCP-1 
      levels and those in anthropometric, metabolic and inflammatory variables in these 
      subjects. RESULTS: Univariate regression analysis showed that serum levels of 
      MCP-1 were positively associated with AGEs (r=0.386, p<0.001) and sRAGE (r=0.315, 
      p<0.001). After adjusting for age and sex, AGEs (p<0.001) and sRAGE (p<0.05) 
      still remained significant. CONCLUSION: The results demonstrate for the first 
      time that circulating levels of AGEs and sRAGE are independent determinants of 
      serum MCP-1 levels in patients with type 2 diabetes. Our present observations 
      suggest the AGEs-RAGE system may be mainly involved in the elevation of MCP-1 in 
      type 2 diabetic patients.
CI  - Copyright (c) 2007 John Wiley & Sons, Ltd.
FAU - Nakamura, Kazuo
AU  - Nakamura K
AD  - Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
FAU - Yamagishi, Sho-ichi
AU  - Yamagishi S
FAU - Adachi, Hisashi
AU  - Adachi H
FAU - Matsui, Takanori
AU  - Matsui T
FAU - Kurita-Nakamura, Yayoi
AU  - Kurita-Nakamura Y
FAU - Takeuchi, Masayoshi
AU  - Takeuchi M
FAU - Inoue, Hiroyoshi
AU  - Inoue H
FAU - Imaizumi, Tsutomu
AU  - Imaizumi T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Glycation End Products, Advanced)
RN  - 0 (Receptor for Advanced Glycation End Products)
RN  - 0 (Receptors, Immunologic)
SB  - IM
MH  - Aged
MH  - Chemokine CCL2/*blood
MH  - Diabetes Mellitus, Type 2/*blood
MH  - Female
MH  - Glycation End Products, Advanced/*blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Receptor for Advanced Glycation End Products
MH  - Receptors, Immunologic/*blood
MH  - Regression Analysis
MH  - Solubility
EDAT- 2007/08/19 09:00
MHDA- 2008/03/22 09:00
CRDT- 2007/08/19 09:00
PHST- 2007/08/19 09:00 [pubmed]
PHST- 2008/03/22 09:00 [medline]
PHST- 2007/08/19 09:00 [entrez]
AID - 10.1002/dmrr.766 [doi]
PST - ppublish
SO  - Diabetes Metab Res Rev. 2008 Feb;24(2):109-14. doi: 10.1002/dmrr.766.